BRPI0617830B8 - uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmo - Google Patents
uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmoInfo
- Publication number
- BRPI0617830B8 BRPI0617830B8 BRPI0617830A BRPI0617830A BRPI0617830B8 BR PI0617830 B8 BRPI0617830 B8 BR PI0617830B8 BR PI0617830 A BRPI0617830 A BR PI0617830A BR PI0617830 A BRPI0617830 A BR PI0617830A BR PI0617830 B8 BRPI0617830 B8 BR PI0617830B8
- Authority
- BR
- Brazil
- Prior art keywords
- beta
- compounds
- receptor
- rheumatoid arthritis
- syndromes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Abstract
uso de compostos il-1beta. a presente invenção refere-se a um novo uso de compostos de rompimento ligante il-1(beta)/receptor il-1(beta) (referidos aqui, neste pedido de patente como "compostos il-1beta"); tais como os compostos de pequeno peso molecular que rompem a interação ligante il-1(beta)/receptor il-1(beta), anticorpos il-1(beta) ou anticorpos do receptor de il-1(beta), como, por exemplo, moléculas de ligação de il-1(beta) descritas aqui, por exemplo, os anticorpos descritos aqui, por exemplo, os compostos de ligação de il-1(beta) ou os compostos de ligação aos receptores de il-1(beta), e/ou os compostos de rna que diminuem tanto os níveis dos ligantes de ll-1(beta) como da proteína do receptor de ll-1(beta), para o tratamento e/ou a prevenção de síndromes auto-inflamatórias, como por exemplo, as síndromes da artrite reumatóide juvenil ou artrite reumatóide em adultos e a métodos para o tratamento e/ou a prevenção das síndromes auto-inflamatórias como por exemplo, as síndromes da artrite reumatóide juvenil ou artrite reumatóide em adultos em mamíferos, especificamente seres humanos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73043505P | 2005-10-26 | 2005-10-26 | |
| US60/730,435 | 2005-10-26 | ||
| US74212505P | 2005-12-02 | 2005-12-02 | |
| US60/742,125 | 2005-12-02 | ||
| PCT/US2006/041479 WO2007050607A2 (en) | 2005-10-26 | 2006-10-24 | Novel use of il-1beta compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0617830A2 BRPI0617830A2 (pt) | 2011-08-09 |
| BRPI0617830B1 BRPI0617830B1 (pt) | 2020-10-20 |
| BRPI0617830B8 true BRPI0617830B8 (pt) | 2021-05-25 |
Family
ID=37806690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0617830A BRPI0617830B8 (pt) | 2005-10-26 | 2006-10-24 | uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmo |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US8105587B2 (pt) |
| EP (5) | EP2848258B1 (pt) |
| JP (4) | JP2009513645A (pt) |
| KR (3) | KR101518064B1 (pt) |
| CN (2) | CN101291693B (pt) |
| AU (1) | AU2006306280B2 (pt) |
| BR (1) | BRPI0617830B8 (pt) |
| CA (3) | CA2898369C (pt) |
| CY (4) | CY1113378T1 (pt) |
| DK (2) | DK1940465T3 (pt) |
| ES (3) | ES2944067T3 (pt) |
| HU (2) | HUE036973T2 (pt) |
| IL (4) | IL190545A (pt) |
| JO (2) | JO2826B1 (pt) |
| LT (3) | LT2848258T (pt) |
| LU (2) | LU92326I2 (pt) |
| MA (1) | MA29919B1 (pt) |
| NO (2) | NO345888B1 (pt) |
| NZ (1) | NZ567222A (pt) |
| PH (2) | PH12013501287B1 (pt) |
| PL (2) | PL1940465T3 (pt) |
| PT (2) | PT1940465E (pt) |
| RU (2) | RU2468817C2 (pt) |
| SI (2) | SI1940465T1 (pt) |
| TN (1) | TNSN08189A1 (pt) |
| TR (1) | TR201802449T4 (pt) |
| TW (3) | TWI388335B (pt) |
| WO (1) | WO2007050607A2 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2848258B1 (en) * | 2005-10-26 | 2017-12-13 | Novartis AG | Treatment of familial Mediterranean Fever with anti IL-1beta antibodies |
| AU2012203931B2 (en) * | 2007-05-29 | 2014-04-24 | Novartis Ag | New indications for anti-IL-I-beta therapy |
| EP3406263A1 (en) * | 2007-05-29 | 2018-11-28 | Novartis AG | New indications for anti-il-1beta therapy |
| CA2727171A1 (en) * | 2008-06-06 | 2009-12-10 | Xoma Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AU2010291985B2 (en) | 2009-09-14 | 2016-05-05 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| TW201124427A (en) * | 2009-10-15 | 2011-07-16 | Abbott Lab | IL-1 binding proteins |
| AU2011252883B2 (en) * | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
| WO2012121775A2 (en) * | 2010-12-21 | 2012-09-13 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| EP3426775A1 (en) | 2016-03-10 | 2019-01-16 | Novartis AG | Chemically modified messenger rna's |
| US11162943B2 (en) | 2017-05-31 | 2021-11-02 | Prometheus Biosciences Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| US20190048072A1 (en) | 2017-06-22 | 2019-02-14 | Novartis Ag | USE OF IL-1beta BINDING ANTIBODIES |
| CN112584857A (zh) * | 2018-05-09 | 2021-03-30 | 诺华股份有限公司 | 卡那吉努单抗的用途 |
| WO2020128636A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| JP2022514087A (ja) | 2018-12-21 | 2022-02-09 | ノバルティス アーゲー | ＩＬ－１β結合抗体の使用 |
| TWI793503B (zh) * | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | 抗IL-1β抗體 |
| EP4464329A4 (en) * | 2022-01-10 | 2025-06-11 | GI Innovation, Inc. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES, CONTAINING A GLUCAGON-LIKE PEPTIDE-1 AND AN INTERLEUKIN-1 RECEPTOR ANTAGONIST |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5350683A (en) * | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| EP0690673A4 (en) | 1993-12-14 | 1996-05-29 | Univ Pittsburgh | SYSTEMIC GENETIC TREATMENT OF TISSUE DISEASES |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| JP2003500005A (ja) | 1999-02-10 | 2003-01-07 | インターリューキン ジェネティックス インコーポレイテッド | ＩＬ−１β遺伝子の突然変異に基づく治療および診断 |
| DK1210320T3 (da) * | 1999-07-16 | 2005-01-31 | Leo Pharma As | Aminobenzofenoner som inhibitorer for IL-1beta og TNF-alfa |
| AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| EP2241328A1 (en) * | 2000-05-12 | 2010-10-20 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| SG159378A1 (en) | 2000-11-07 | 2010-03-30 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| EP1423432A4 (en) * | 2001-07-26 | 2006-01-11 | Lilly Co Eli | ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA) |
| EP1450837A4 (en) * | 2001-08-07 | 2006-01-04 | Immunex Corp | INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES |
| ES2385823T3 (es) | 2001-12-01 | 2012-08-01 | Iskra Wind Turbines Ltd. | Generador de corriente alterna síncrono que incorpora un mecanismo de frenado |
| KR200268109Y1 (ko) | 2001-12-06 | 2002-03-15 | 김정훈 | 편평형 무정류자 진동모터 |
| JP2005519917A (ja) | 2002-02-01 | 2005-07-07 | オメロス コーポレイション | 軟骨分解の全身阻害のための組成物および方法 |
| BR0307544A (pt) | 2002-02-01 | 2004-12-07 | Ariad Gene Therapeutics Inc | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos |
| CA2474360A1 (en) * | 2002-02-11 | 2003-08-21 | Arkion Life Sciences Llc | Purified cytokine inhibitory factor |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| WO2004052359A1 (en) | 2002-12-09 | 2004-06-24 | The Board Of Regents Of The University Of Texas System | Methods for selectively inhibiting janus tyrosine kinase 3 (jak3) |
| CN1780855B (zh) * | 2003-01-24 | 2011-03-30 | 应用分子进化公司 | 人IL-1β拮抗剂 |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| AU2005249503B2 (en) * | 2003-11-10 | 2011-08-25 | Vertex Pharmaceuticals Incorporated | ICE inhibitors for the treatment of autoinflammatory diseases |
| AU2004290413A1 (en) | 2003-11-10 | 2005-05-26 | Vertex Pharmaceuticals Incorporated | Methods for monitoring IL-18 |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| AU2005216298B2 (en) * | 2004-02-26 | 2010-09-02 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
| AU2005249570B2 (en) * | 2004-06-04 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat autoinflammatory disease |
| JP2009501128A (ja) | 2005-01-20 | 2009-01-15 | ユニバーシティー オブ ロチェスター | 炎症疾患および炎症障害の研究および処置のための組成物および方法 |
| EP2371967B1 (en) | 2005-03-18 | 2015-06-03 | DSM IP Assets B.V. | Production of carotenoids in oleaginous yeast and fungi |
| ES2569917T3 (es) | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
| EP2848258B1 (en) * | 2005-10-26 | 2017-12-13 | Novartis AG | Treatment of familial Mediterranean Fever with anti IL-1beta antibodies |
-
2006
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/en active Active
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/en active Active
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 CA CA2898369A patent/CA2898369C/en active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 CA CA2963828A patent/CA2963828A1/en not_active Abandoned
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/en not_active Ceased
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 CA CA2626214A patent/CA2626214C/en active Active
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active Active
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/en active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en not_active IP Right Cessation
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Ceased
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 EP EP06826560A patent/EP1940465B1/en active Active
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/en active Pending
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 EP EP10181100A patent/EP2332577A1/en not_active Withdrawn
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active Active
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
-
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
-
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
-
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
-
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287B1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I2/el unknown
-
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
-
2015
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
-
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
-
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
-
2018
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I2/el unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
-
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
-
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en not_active Abandoned
-
2025
- 2025-05-23 US US19/217,696 patent/US20260125463A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120018T1 (el) | Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα | |
| Das et al. | Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy | |
| MX2009012948A (es) | Nuevas indicaciones para la terapia anti-il-1-beta. | |
| CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| DE602005021072D1 (de) | Adzyme und deren verwendungen | |
| EA201290123A1 (ru) | Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения | |
| BRPI0606398A (pt) | moléculas de criptoligação | |
| MA40041B1 (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
| BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
| BRPI0513078B8 (pt) | anticorpo igg que se liga a il-17 humana e composição líquida | |
| BRPI0818437A2 (pt) | Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma | |
| BR112018074838A2 (pt) | anticorpos anti-ige | |
| CY1118896T1 (el) | Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9 | |
| BRPI0619153B8 (pt) | derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica | |
| BR112014032999A2 (pt) | optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos | |
| BRPI0313733A8 (pt) | Uso da proteína n beta cinase | |
| IL194550A (en) | Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| BRPI0611800A2 (pt) | formulaÇço estÁvel de anticorpo | |
| BR112016004073A8 (pt) | Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3 | |
| BRPI0410129A (pt) | uso terapêutico de anticorpos anti-cs1 | |
| BRPI0611984A2 (pt) | uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo | |
| BRPI0510848A (pt) | derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |